Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Says it has partnered with global biopharma services company Eurofins Genomics. The move is intended to complete RNA sequencing of respiratory syncytial virus disease progression samples from human viral challenge studies for Poolbeg. Company says it already has RNA sequencing data for influenza which covers the full disease cycle and presents significant opportunities to unlock insights into diseases which will magnify the power of the AI analysis.
Says project with Eurofins is expected to be completed by the end of 2021 and will involve next generation RNA sequencing of RSV transcriptomics to help tracking of the biology of immune responses in molecular detail during infection.
Chief Executive Officer Jeremy Skillington says: "This is an exciting step in our AI data analysis programme. The deep genetic analysis of RSV progression will be key information to feed into AI drug and target discovery tools. We already have similar data for influenza so we will now have complete discovery datasets for both influenza and RSV.
"Our AI analysis will be breaking new ground in data-driven drug discovery as it will be the first time that human challenge trial immune data is used in this way. Having the sequencing specially tailored to work with AI platforms will enable us to discover potential new drug candidates for both diseases in a quicker and more cost-effective way."
Current stock price: 10.30 pence, up 3.0% from July's IPO price
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Poolbeg Pharma (POLB)